TY  - JOUR
AU  - Radojević, Branislava S.
AU  - Jančić, Ivan
AU  - Savić, Miroslav
AU  - Kostić, Vladimir S.
AU  - Dragašević-Mišković, Nataša T.
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5581
AB  - Catechol-O-methyltransferase (COMT) is one of the cardinal enzymes in the degradation
of catecholamines and levodopa. Genetic variants of the COMT gene may affect COMT enzyme
activity. The most examined COMT gene polymorphism is the nonsynonymous single nucleotide
polymorphism (SNP) in exon 4 (Val108/158Met; rs4680). This highly functional polymorphism
is responsible for fourfold variations in enzyme activity and dopamine catabolism. Recent data
suggested that even synonymous SNPs of the COMT gene can lead to changes in enzyme activity.
Genetically determined COMT activity can affect an individual's response to levodopa therapy
and carries the risk of complications from prolonged levodopa use in Parkinson's disease (PD)
patients. Identifying at-risk individuals through genetic susceptibility markers could help to
prevent the development of levodopa-induced complications in PD.
AB  - Katehol-O-metiltransferaza (engl. catechol-O-methyltransferase, COMT) je jedan od
glavnih enzima u razgradnji kateholamina i levodope. Genetske varijante COMT gena mogu
uticati na aktivnost COMT enzima. Polimorfizam COMT gena koji je najviše proučavan je
nesinonimni jednonukleotidni polimorfizam (engl. single nucleotide polymorphism, SNP) u
egzonu 4 (Val108/158Met; rs4680). Ovaj visoko funkcionalni polimorfizam odgovoran je za
četvorostruke varijacije u aktivnosti enzima i katabolizmu dopamina. Nedavni podaci sugerišu da
čak i sinonimni SNP COMT gena mogu da dovedu do promena u aktivnosti enzima. Genetski
određene razlike u COMT aktivnosti mogu uticati na odgovor pojedinca na terapiju levodopom i
nose rizik od komplikacija dugotrajne primene levodope kod pacijenata sa Parkinsonovom
bolešću (PB). Identifikacija osoba u riziku putem markera genetske osetljivosti može pomoći u
prevenciji komplikacija izazvanih levodopom kod PB.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
PB  - Beograd : Univerzitet u Beogradu - Farmaceutski fakultet
T2  - Arhiv za farmaciju
T1  - Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge
T1  - Udruženost polimorfizama gena za katehol-O- metiltransferazu sa terapijskim odgovorom i komplikacijama izazvanim levodopom kod Parkinsonove bolesti: Rezime sadašnjih saznanja
VL  - 74
IS  - 1
SP  - 23
EP  - 37
DO  - 10.5937/arhfarm74-45472
ER  - 

@article{
author = "Radojević, Branislava S. and Jančić, Ivan and Savić, Miroslav and Kostić, Vladimir S. and Dragašević-Mišković, Nataša T.",
year = "2024",
abstract = "Catechol-O-methyltransferase (COMT) is one of the cardinal enzymes in the degradation
of catecholamines and levodopa. Genetic variants of the COMT gene may affect COMT enzyme
activity. The most examined COMT gene polymorphism is the nonsynonymous single nucleotide
polymorphism (SNP) in exon 4 (Val108/158Met; rs4680). This highly functional polymorphism
is responsible for fourfold variations in enzyme activity and dopamine catabolism. Recent data
suggested that even synonymous SNPs of the COMT gene can lead to changes in enzyme activity.
Genetically determined COMT activity can affect an individual's response to levodopa therapy
and carries the risk of complications from prolonged levodopa use in Parkinson's disease (PD)
patients. Identifying at-risk individuals through genetic susceptibility markers could help to
prevent the development of levodopa-induced complications in PD., Katehol-O-metiltransferaza (engl. catechol-O-methyltransferase, COMT) je jedan od
glavnih enzima u razgradnji kateholamina i levodope. Genetske varijante COMT gena mogu
uticati na aktivnost COMT enzima. Polimorfizam COMT gena koji je najviše proučavan je
nesinonimni jednonukleotidni polimorfizam (engl. single nucleotide polymorphism, SNP) u
egzonu 4 (Val108/158Met; rs4680). Ovaj visoko funkcionalni polimorfizam odgovoran je za
četvorostruke varijacije u aktivnosti enzima i katabolizmu dopamina. Nedavni podaci sugerišu da
čak i sinonimni SNP COMT gena mogu da dovedu do promena u aktivnosti enzima. Genetski
određene razlike u COMT aktivnosti mogu uticati na odgovor pojedinca na terapiju levodopom i
nose rizik od komplikacija dugotrajne primene levodope kod pacijenata sa Parkinsonovom
bolešću (PB). Identifikacija osoba u riziku putem markera genetske osetljivosti može pomoći u
prevenciji komplikacija izazvanih levodopom kod PB.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije, Beograd : Univerzitet u Beogradu - Farmaceutski fakultet",
journal = "Arhiv za farmaciju",
title = "Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge, Udruženost polimorfizama gena za katehol-O- metiltransferazu sa terapijskim odgovorom i komplikacijama izazvanim levodopom kod Parkinsonove bolesti: Rezime sadašnjih saznanja",
volume = "74",
number = "1",
pages = "23-37",
doi = "10.5937/arhfarm74-45472"
}

Radojević, B. S., Jančić, I., Savić, M., Kostić, V. S.,& Dragašević-Mišković, N. T.. (2024). Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 74(1), 23-37.
https://doi.org/10.5937/arhfarm74-45472

Radojević BS, Jančić I, Savić M, Kostić VS, Dragašević-Mišković NT. Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge. in Arhiv za farmaciju. 2024;74(1):23-37.
doi:10.5937/arhfarm74-45472 .

Radojević, Branislava S., Jančić, Ivan, Savić, Miroslav, Kostić, Vladimir S., Dragašević-Mišković, Nataša T., "Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge" in Arhiv za farmaciju, 74, no. 1 (2024):23-37,
https://doi.org/10.5937/arhfarm74-45472 . .

TY  - JOUR
AU  - Radojević, Branislava
AU  - Dragašević-Mišković, Nataša T.
AU  - Milovanović, Andona
AU  - Svetel, Marina
AU  - Petrović, Igor
AU  - Pešić, Maja
AU  - Tomić, Aleksandra
AU  - Stanisavljević, Dejana
AU  - Savić, Miroslav
AU  - Kostić, Vladimir S.
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4329
AB  - Objectives: Adherence to medication is an important factor that can influence Parkinson's disease (PD) control. We aimed to explore patients' adherence to antiparkinsonian medication and determine factors that might affect adherence to medications among PD patients. Methods: A cross-sectional, exploratory survey of PD patients treated with at least one antiparkinsonian drug and with a total score of MoCA (Montreal Cognitive Assessment) ≥26 was conducted. The final sample included 112 PD patients. A patient's adherence was assessed through ARMS (Adherence to Refills and Medications Scale). ARMS scores higher than 12 were assumed lower adherence. In addition, each patient underwent neurological examination, assessment of depression, anxiety, and evaluation of the presence of PD nonmotor symptoms. Results: The mean ARDS value in our cohort was 14.9 ± 2.5. Most PD patients (74.1%) reported lower adherence to their medication. Participants in the lower adherence group were younger at PD onset, had significantly higher UPDRS (Unified PD Rating Scale) scores, as well as UPDRS III and UPDRS IV subscores, HARS (Hamilton Anxiety Rating Scale), and NMSQuest (Non-Motor Symptoms Questionnaire for PD) scores compared to the fully adherent group (p=0.013, p=0.017, p=0.041, p=0.043, and p=0.023, respectively). Among nonmotor PD symptoms, the presence of cardiovascular, apathy/attention-deficit/memory disorders, hallucinations/delusions, and problems regarding changes in weight, diplopia, or sweating were associated with lower adherence. Multivariate regression analysis revealed depression as the strongest independent predictor of lower adherence. Conclusion: Depressed PD patients compared to PD patients without clinical depression had a three times higher risk for lower adherence to pharmacotherapy. Recognition and adequate treatment of depression might result in improved adherence.
PB  - Hindawi
T2  - International journal of clinical practice
T1  - Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale
VL  - 2022
DO  - 10.1155/2022/6741280
ER  - 

@article{
author = "Radojević, Branislava and Dragašević-Mišković, Nataša T. and Milovanović, Andona and Svetel, Marina and Petrović, Igor and Pešić, Maja and Tomić, Aleksandra and Stanisavljević, Dejana and Savić, Miroslav and Kostić, Vladimir S.",
year = "2022",
abstract = "Objectives: Adherence to medication is an important factor that can influence Parkinson's disease (PD) control. We aimed to explore patients' adherence to antiparkinsonian medication and determine factors that might affect adherence to medications among PD patients. Methods: A cross-sectional, exploratory survey of PD patients treated with at least one antiparkinsonian drug and with a total score of MoCA (Montreal Cognitive Assessment) ≥26 was conducted. The final sample included 112 PD patients. A patient's adherence was assessed through ARMS (Adherence to Refills and Medications Scale). ARMS scores higher than 12 were assumed lower adherence. In addition, each patient underwent neurological examination, assessment of depression, anxiety, and evaluation of the presence of PD nonmotor symptoms. Results: The mean ARDS value in our cohort was 14.9 ± 2.5. Most PD patients (74.1%) reported lower adherence to their medication. Participants in the lower adherence group were younger at PD onset, had significantly higher UPDRS (Unified PD Rating Scale) scores, as well as UPDRS III and UPDRS IV subscores, HARS (Hamilton Anxiety Rating Scale), and NMSQuest (Non-Motor Symptoms Questionnaire for PD) scores compared to the fully adherent group (p=0.013, p=0.017, p=0.041, p=0.043, and p=0.023, respectively). Among nonmotor PD symptoms, the presence of cardiovascular, apathy/attention-deficit/memory disorders, hallucinations/delusions, and problems regarding changes in weight, diplopia, or sweating were associated with lower adherence. Multivariate regression analysis revealed depression as the strongest independent predictor of lower adherence. Conclusion: Depressed PD patients compared to PD patients without clinical depression had a three times higher risk for lower adherence to pharmacotherapy. Recognition and adequate treatment of depression might result in improved adherence.",
publisher = "Hindawi",
journal = "International journal of clinical practice",
title = "Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale",
volume = "2022",
doi = "10.1155/2022/6741280"
}

Radojević, B., Dragašević-Mišković, N. T., Milovanović, A., Svetel, M., Petrović, I., Pešić, M., Tomić, A., Stanisavljević, D., Savić, M.,& Kostić, V. S.. (2022). Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale. in International journal of clinical practice
Hindawi., 2022.
https://doi.org/10.1155/2022/6741280

Radojević B, Dragašević-Mišković NT, Milovanović A, Svetel M, Petrović I, Pešić M, Tomić A, Stanisavljević D, Savić M, Kostić VS. Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale. in International journal of clinical practice. 2022;2022.
doi:10.1155/2022/6741280 .

Radojević, Branislava, Dragašević-Mišković, Nataša T., Milovanović, Andona, Svetel, Marina, Petrović, Igor, Pešić, Maja, Tomić, Aleksandra, Stanisavljević, Dejana, Savić, Miroslav, Kostić, Vladimir S., "Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale" in International journal of clinical practice, 2022 (2022),
https://doi.org/10.1155/2022/6741280 . .